Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome

Ellen K RitchieLeukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USAAbstract: The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ritchie EK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	geriatrics myelodysplastic syndrome acute myeloid leukemia azacitidine supportive care Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/acfd2aea969745b295f77e7d57acbbd2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:acfd2aea969745b295f77e7d57acbbd2
record_format	dspace
spelling	oai:doaj.org-article:acfd2aea969745b295f77e7d57acbbd22021-12-02T02:40:13ZSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome1178-1998https://doaj.org/article/acfd2aea969745b295f77e7d57acbbd22012-06-01T00:00:00Zhttps://www.dovepress.com/safety-and-efficacy-of-azacitidine-in-the-treatment-of-elderly-patient-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ellen K RitchieLeukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USAAbstract: The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an allogeneic stem cell transplant for potential cure of the disease. The focus for the treatment of older patients with MDS is therefore not curative, but rather alleviation of symptoms, improvement in quality of life, maintenance or improvement of functional status, and continued independent living. Prolongation of survival is only important if functional status and quality of life can be maintained, and there is greater risk of losing these outcomes in elderly patients. Azacitidine is an important drug for the treatment of older patients with MDS. Data from the AZA-001 trial has shown a survival benefit for patients with high-risk disease treated with azacitidine. Importantly, treatment has also been shown to improve quality of life for MDS patients. Subset analysis of the data has shown that the drug can be used safely in even the oldest patients with MDS and is superior to treatment with other established regimens, such as low-dose cytarabine. Given the delay between the initiation of treatment and the clinical response, patients may need aggressive supportive care with antiemetics, prophylactic antibiotics, and transfusions to maintain them through therapy. Azacitidine provides a better quality of response when it is used beyond the first response, so ongoing treatment is generally recommended in responding patients. A new oral preparation of the drug is in development that will make the treatment more feasible and comfortable for elderly patients.Keywords: geriatrics, myelodysplastic syndrome, acute myeloid leukemia, azacitidine, supportive careRitchie EKDove Medical Pressarticlegeriatricsmyelodysplastic syndromeacute myeloid leukemiaazacitidinesupportive careGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 7, Pp 165-173 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	geriatrics myelodysplastic syndrome acute myeloid leukemia azacitidine supportive care Geriatrics RC952-954.6
spellingShingle	geriatrics myelodysplastic syndrome acute myeloid leukemia azacitidine supportive care Geriatrics RC952-954.6 Ritchie EK Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
description	Ellen K RitchieLeukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USAAbstract: The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an allogeneic stem cell transplant for potential cure of the disease. The focus for the treatment of older patients with MDS is therefore not curative, but rather alleviation of symptoms, improvement in quality of life, maintenance or improvement of functional status, and continued independent living. Prolongation of survival is only important if functional status and quality of life can be maintained, and there is greater risk of losing these outcomes in elderly patients. Azacitidine is an important drug for the treatment of older patients with MDS. Data from the AZA-001 trial has shown a survival benefit for patients with high-risk disease treated with azacitidine. Importantly, treatment has also been shown to improve quality of life for MDS patients. Subset analysis of the data has shown that the drug can be used safely in even the oldest patients with MDS and is superior to treatment with other established regimens, such as low-dose cytarabine. Given the delay between the initiation of treatment and the clinical response, patients may need aggressive supportive care with antiemetics, prophylactic antibiotics, and transfusions to maintain them through therapy. Azacitidine provides a better quality of response when it is used beyond the first response, so ongoing treatment is generally recommended in responding patients. A new oral preparation of the drug is in development that will make the treatment more feasible and comfortable for elderly patients.Keywords: geriatrics, myelodysplastic syndrome, acute myeloid leukemia, azacitidine, supportive care
format	article
author	Ritchie EK
author_facet	Ritchie EK
author_sort	Ritchie EK
title	Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
title_short	Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
title_full	Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
title_fullStr	Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
title_full_unstemmed	Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
title_sort	safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/acfd2aea969745b295f77e7d57acbbd2
work_keys_str_mv	AT ritchieek safetyandefficacyofazacitidineinthetreatmentofelderlypatientswithmyelodysplasticsyndrome
_version_	1718402311764574208

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome

Ejemplares similares